MX2016002823A - Metodos y composiciones para vacunas vectorizadas virales. - Google Patents

Metodos y composiciones para vacunas vectorizadas virales.

Info

Publication number
MX2016002823A
MX2016002823A MX2016002823A MX2016002823A MX2016002823A MX 2016002823 A MX2016002823 A MX 2016002823A MX 2016002823 A MX2016002823 A MX 2016002823A MX 2016002823 A MX2016002823 A MX 2016002823A MX 2016002823 A MX2016002823 A MX 2016002823A
Authority
MX
Mexico
Prior art keywords
methods
compositions
vaccine
vector
vectored vaccines
Prior art date
Application number
MX2016002823A
Other languages
English (en)
Spanish (es)
Inventor
Chu Tang De-
Original Assignee
Altimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altimmune Inc filed Critical Altimmune Inc
Publication of MX2016002823A publication Critical patent/MX2016002823A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
MX2016002823A 2013-09-06 2014-09-05 Metodos y composiciones para vacunas vectorizadas virales. MX2016002823A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874505P 2013-09-06 2013-09-06
PCT/US2014/054234 WO2015035128A1 (en) 2013-09-06 2014-09-05 Methods and compositions for viral vectored vaccines

Publications (1)

Publication Number Publication Date
MX2016002823A true MX2016002823A (es) 2016-12-16

Family

ID=52625855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002823A MX2016002823A (es) 2013-09-06 2014-09-05 Metodos y composiciones para vacunas vectorizadas virales.

Country Status (8)

Country Link
US (1) US20150071964A1 (cg-RX-API-DMAC7.html)
EP (1) EP3041503A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016529316A (cg-RX-API-DMAC7.html)
KR (1) KR20160049010A (cg-RX-API-DMAC7.html)
AU (1) AU2014315124A1 (cg-RX-API-DMAC7.html)
CA (1) CA2923406A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016002823A (cg-RX-API-DMAC7.html)
WO (1) WO2015035128A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2020210149A1 (en) * 2019-04-06 2020-10-15 Altimmune Inc Broad and long-lasting influenza vaccine
EP4138902A4 (en) * 2020-04-20 2024-06-12 Greffex, Inc. MANUFACTURE OF BROADLY REACTIVE CORONAVIRUS VACCINES AND CORRESPONDING DESIGNS AND USES
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2712673C2 (de) * 1977-03-23 1983-12-15 Krauss U. Reichert Gmbh + Co Kg Spezialmaschinenfabrik, 7012 Fellbach Stoßmessermaschine
US20030134815A1 (en) * 1991-08-20 2003-07-17 The Govt. Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Adenovirus mediated transfer of genes to the gastrointestinal tract
US20050271689A1 (en) * 2003-07-11 2005-12-08 Chun-Ming Huang Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
US7439349B2 (en) * 2002-07-03 2008-10-21 Andres Salazar Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof
US8592391B2 (en) * 2003-07-01 2013-11-26 Andres Salazar Method for therapeutic, clinical and veterinary use poly-ICLC
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
JP2008541730A (ja) * 2005-05-23 2008-11-27 ヴァクシン インコーポレイテッド 高力価かつ複製コンピテントアデノウイルス不含である組換えアデノウイルスベクターの迅速な作成法
JP2009512421A (ja) * 2005-08-15 2009-03-26 ヴァクシン インコーポレイテッド 非複製性ベクターワクチン投与による鳥類への免疫方法
RS54843B1 (sr) * 2006-02-28 2016-10-31 Vaxart Inc Himerni adenovirusni vektori i dsrna kao tlr3 agonist
AU2009253780B2 (en) * 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
KR20110081222A (ko) * 2008-09-26 2011-07-13 어번 유니버시티 비복제성 벡터화된 백신의 점막 투여에 의한 조류의 면역화
JP5762307B2 (ja) * 2009-03-31 2015-08-12 国立感染症研究所長 経鼻投与用ワクチンを用いるインフルエンザの予防方法
JP5908397B2 (ja) * 2009-06-09 2016-04-26 デフィルス、インコーポレイテッドＤｅｆｙｒｕｓ， Ｉｎｃ． 病原体感染を予防又は治療するためのインターフェロン投与
KR20200008014A (ko) * 2011-03-21 2020-01-22 알티뮨 인크. 급속 및 지속적 면역학적제제-치료제

Also Published As

Publication number Publication date
WO2015035128A1 (en) 2015-03-12
JP2016529316A (ja) 2016-09-23
EP3041503A4 (en) 2017-06-07
KR20160049010A (ko) 2016-05-04
AU2014315124A1 (en) 2016-04-07
EP3041503A1 (en) 2016-07-13
CA2923406A1 (en) 2015-03-12
US20150071964A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
AR118725A2 (es) Vectores para expresión de antígenos asociados a próstata
PH12018500127A1 (en) Vaccine compositions
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
EP4218807A3 (en) Zika virus vaccine
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2015142671A3 (en) Influenza virus vectors and uses therefor
HK1225631A1 (zh) 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
WO2013054199A3 (en) Cmv antigens and uses thereof
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
PH12015500956A1 (en) Novel mucosal adjuvants and delivery systems
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
CL2018000609A1 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue.
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
AR090450A1 (es) Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteina c mutada y usos de la misma
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.